841281-92-3

Basic information

• Product Name: 1-Piperazinecarboxylic acid, 4-[4-chloro-6-(cyclohexylmethylamino)-1,3,5-triazin-2-yl]-, 1,1-dimethylethyl ester
• CAS NO: 841281-92-3
• Molecular Formula: C19H31ClN6O2
• Molecular Weight: 410.947
• Mol File: 841281-92-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-Piperazinecarboxylic acid, 4-[4-chloro-6-(cyclohexylmethylamino)-1,3,5-triazin-2-yl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxylic acid, 4-[4-chloro-6-(cyclohexylmethylamino)-1,3,5-triazin-2-yl]-, 1,1-dimethylethyl ester(841281-92-3)
• EPA Substance Registry System: 1-Piperazinecarboxylic acid, 4-[4-chloro-6-(cyclohexylmethylamino)-1,3,5-triazin-2-yl]-, 1,1-dimethylethyl ester(841281-92-3)

Safety Data

• Hazardous Substances Data: 841281-92-3(Hazardous Substances Data)

Upstream product

• 100-60-7 N-methylcyclohexylamine 
• 271592-49-5 tert-butyl-4-(4,6-dichloro-1,3,5-triazin-2-yl)-1-piperazinecarboxylate 

Downstream Products

• 841281-93-4 2-chloro-4-(4-tert-butoxycarbonylpiperazin-1-yl)-6-(N-methylcyclohexylamino)-1,3,5-triazine-2-carbonitrile 

Relevant articles and documents

2-CYANO-1,3,5-TRIAZINE-4,6-DIAMINE DERIVATIVES

The invention relates to the use of a 2-cyano-1,3,5-triazine -4,6-diamine derivative having general formula (I), wherein R1 is (C1-6)alkyl, (C3-8)cycloalkyl, aryl, aryl(C1-4)alkyl, aryloxy(C1-4)alkyl, heteroaryl or heteroaryloxy(C1-4)alkyl; R2 is H or (C1-4)alkyl; or R1 and R2 together with the nitrogen to which they are bound form a 4-8 membered heterocyclic ring, optionally further comprising 1 or more heteroatoms selected from O, S or NR5, which ring may be substituted with (C1-4)alkyl, (C3-8)cycloalkyl, aryl, aryl(C1-4)alkyl or NR6R7,and which ring may be fused to a benzene ring; R3 is (C1-6)alkyl, (C3-8) cycloalkyl (optionally comprising 1 or more heteroatoms selected from O, S or NR8), aryl, aryl(C1-4)alkyl or heteroaryl; R4 is H or (C1-4)alkyl; or R3 and R4 together with the nitrogen to which they are bound form a 4-8 membered heterocyclic ring, optionally further comprising 1 or more heteroatoms selected from O, S or NR9; R5, R8 and R9 are independently H, (C1-4)alkyl, (C3-8) cycloalkyl, aryl or aryl(C1-4)alkyl; R6 and R7 are independently H or (C1-4)alkyl; or R6 and R7 form together with the nitrogen to which they are bound a 4-8 membered heterocyclic ring; or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of osteoporosis and atherosclerosis.